Skip to main content
    T

    Treace Medical Concepts Inc (TMCI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.42
    -0.85 (-16.13%)

    Market Cap: $345.50M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Treace Medical Concepts Inc (TMCI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Treace Medical Concepts reported revenue of $212.69M for the fiscal year ended Dec 31, 2025, up 1.6% from the year before. That year, net income was -$59.00M with a net margin of -27.7%, operating cash flow was -$15.97M and free cash flow was -$29.49M. The quarter ended Sep 30, 2026 had revenue of $48.25M and net income of -$12.57M.

    Revenue and Margins

    The operating margin was -25.5% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from $39.42M, a compound annual rate of 32.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$212.69M+1.6%79.8%-25.5%-27.7%
    Dec 2024$209.36M+11.9%80.4%-26.6%-26.6%
    Dec 2023$187.12M+31.9%81.2%-27.5%-26.5%
    Dec 2022$141.84M+50.2%82.0%-24.6%-30.2%
    Dec 2021$94.42M+64.6%82.1%-17.5%-21.8%
    Dec 2020$57.37M+45.5%78.3%1.5%-6.4%
    Dec 2019$39.42MN/A80.6%-9.0%-10.8%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$212.69M$209.36M$187.12M$141.84M$94.42M$57.37M$39.42M
    Cost of revenue$42.94M$41.09M$35.18M$25.53M$16.89M$12.47M$7.63M
    Gross profit$169.75M$168.26M$151.94M$116.31M$77.53M$44.90M$31.79M
    Research and development$20.28M$20.59M$15.44M$13.58M$10.20M$5.85M$5.07M
    Operating income-$54.15M-$55.69M-$51.43M-$34.84M-$16.51M$855.00K-$3.54M
    Net income-$59.00M-$55.74M-$49.53M-$42.81M-$20.55M-$3.67M-$4.26M
    EBITDA-$43.36M-$48.24M-$47.19M-$33.00M-$15.65M$2.29M-$2.60M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$48.25M$45.38M$47.20M$62.52M$50.21M$47.39M$52.57M$68.71M$45.09M$44.45M$51.11M$62.21M
    Gross profit$38.35M$35.61M$37.41M$50.40M$39.71M$37.75M$41.89M$55.48M$36.13M$35.67M$40.98M$50.74M
    Operating income-$11.53M-$14.96M-$17.17M-$5.92M-$15.68M-$16.97M-$15.58M-$204.00K-$15.13M-$21.38M-$18.97M-$6.78M
    Net income-$12.57M-$15.87M-$17.96M-$9.39M-$16.29M-$17.40M-$15.92M-$501.00K-$15.36M-$21.21M-$18.68M-$6.28M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, long-term debt of $55.58M exceeded cash and equivalents by $44.88M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$190.58M$217.09M$251.91M$159.02M$140.82M$41.81M$29.72M
    Current assets$132.05M$161.40M$198.36M$133.40M$137.97M$40.98M$28.57M
    Cash and equivalents$10.71M$11.35M$12.98M$19.47M$105.83M$18.08M$12.14M
    Total liabilities$103.25M$104.20M$113.97M$98.50M$47.75M$41.03M$26.55M
    Short-term debtN/A$413.00K$1.40M$339.00KN/A$1.79MN/A
    Long-term debt$55.58M$53.31M$53.01M$52.71M$29.36M$29.19M$19.22M
    Shareholder equity$87.33M$112.89M$137.94M$60.53M$93.07M$776.00K$3.16M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$179.30M$181.06M$184.10M$190.58M$196.59M$206.44M$205.85M$217.09M$212.92M$226.08M$242.73M$251.91M
    Total liabilities$117.65M$113.32M$106.91M$103.25M$107.40M$108.83M$100.50M$104.20M$108.02M$113.94M$116.33M$113.97M
    Cash and equivalents$7.76M$12.61M$9.54M$10.71M$7.69M$8.05M$13.37M$11.35M$12.11M$18.18M$9.33M$12.98M
    Shareholder equity$61.65M$67.74M$77.19M$87.33M$89.19M$97.61M$105.34M$112.89M$104.91M$112.14M$126.39M$137.94M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$15.97M-$37.17M-$34.58M-$30.65M-$17.19M-$4.49M-$7.67M
    Capital expenditures$13.52M$11.59M$11.46M$14.84M$2.71M$1.07M$1.21M
    Free cash flow-$29.49M-$48.76M-$46.03M-$45.49M-$19.90M-$5.56M-$8.88M
    Dividends paid$0$0$0N/A$7.93MN/AN/A
    Investing cash flow$13.25M$35.38M-$81.30M-$76.52M-$2.71M-$1.07M-$1.21M
    Financing cash flow$2.08M$160.00K$109.38M$20.81M$107.65M$11.50M$19.74M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.25M-$4.70M$7.24M-$8.03M-$9.09M-$3.05M$4.20M-$4.21M-$11.84M-$13.90M-$7.22M$532.00K
    Capital expenditures$2.17M$2.20M$3.06M$2.40M$2.81M$4.77M$3.54M$3.07M$2.86M$1.73M$3.93M$2.25M
    Free cash flow-$5.43M-$6.90M$4.18M-$10.42M-$11.90M-$7.82M$655.00K-$7.28M-$14.71M-$15.63M-$11.15M-$1.72M
    Last 12 quarters

    Frequently Asked Questions About TMCI

    What is Treace Medical Concepts' annual revenue?

    Treace Medical Concepts reported revenue of $212.69M for the fiscal year ended Dec 31, 2025.

    How fast is Treace Medical Concepts' revenue growing?

    Revenue was up 1.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 14.5%.

    Is Treace Medical Concepts profitable?

    No. Treace Medical Concepts reported net income of -$59.00M for the fiscal year ended Dec 31, 2025, with a net margin of -27.7%.

    How much free cash flow does TMCI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$15.97M minus capital expenditures of $13.52M produced free cash flow of -$29.49M.

    How much debt does Treace Medical Concepts have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $55.58M and cash and equivalents of $10.71M.